Goldman Sachs sets new price target for Biogen shares in bold bet against Alzheimer’s
Biogen (NASDAQ: BIIB) has had a rough few years. Its multiple sclerosis franchise has been losing market share to generics and biosimilars, revenue has been trending downward, and the stock spent much of 2025 trading near multi-year lows. So when Goldman Sachs raises its price target to $250, it’s worth asking what the bank is…